Blend peptides

9 peptides tagged blend. Each page carries the dosing reference, mechanism, evidence grade and references.

PeptideLab is an educational platform for learning about peptides. The information here is for educational and research purposes only. It is not medical advice, diagnosis, or treatment, and PeptideLab does not claim to diagnose, treat, cure, or prevent any disease or health condition. Many peptides discussed have not been approved for human use by the FDA or other regulatory bodies. Consult a qualified healthcare professional before making any health-related decision.

  • BPC-157 + TB-500 + GHK-Cu (Glow Blend)

    Vial blend of BPC-157, TB-500 (Ac-LKKTETQ) and GHK-Cu, sold mostly as 70 mg (10/10/50 mg); each component has animal or cell data, and no study has tested the three together.

    Evidence: Preclinical

  • BPC-157 + TB-500 + KPV + GHK-Cu (KLOW Blend)

    Vial blend of BPC-157, TB-500 (Ac-LKKTETQ), KPV and GHK-Cu, sold as 80 mg (10/10/10/50 mg); each component has animal or cell data, and no study has tested the four together.

    Evidence: Preclinical

  • BPC-157 + TB-500 Blend

    Vial blend of BPC-157 and TB-500 (Ac-LKKTETQ), two peptides with rodent tissue-repair data; the one rat study of the pair found no added benefit over either alone.

    Evidence: Preclinical

  • CJC-1295 + GHRP-2 Blend

    Vial blend of CJC-1295 without DAC (Mod GRF 1-29) and GHRP-2 (pralmorelin), 5 mg each; GHRP-2 raised GH and appetite in human studies, and no study has tested the pair.

    Evidence: Preclinical

  • CJC-1295 + GHRP-6 Blend

    Vial blend of CJC-1295 without DAC (Mod GRF 1-29) and GHRP-6, 5 mg each; GHRP-6 raised GH in men and synergized with GHRH, and no study has tested this pair.

    Evidence: Preclinical

  • CJC-1295 + Ipamorelin Blend

    Vial blend of CJC-1295 without DAC (Mod GRF 1-29) and ipamorelin, sold as 10 mg (5 mg each); the two act on separate GH-releasing receptors, and no study has tested the pair.

    Evidence: Preclinical

  • Fragment 176-191 + Mod GRF + Ipamorelin

    Vial blend of a GH fragment sold as 176-191, Mod GRF 1-29 and ipamorelin (12 mg: 6/3/3 mg); fat-loss claims rest on rodent data, and no study has tested the mix.

    Evidence: Preclinical

  • Sermorelin + Ipamorelin Blend

    Vial blend of sermorelin (GHRH 1-29) and ipamorelin, 5 mg each; sermorelin raised GH and IGF-1 in older men, ipamorelin's only RCT was negative, and no study has tested the pair.

    Evidence: Preclinical

  • Tesamorelin + Ipamorelin Blend

    Vial blend of tesamorelin and ipamorelin (vendors sell 6/2 mg and 10/3 mg); tesamorelin cut visceral fat in HIV phase 3 trials, and no study has tested the pair.

    Evidence: Preclinical

Other categories